Expand XFOR Menu
XFOR MENU

XFOR Latest Press Releases

-- September 9, 2026 --

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference Globe Newswire 7:00 AM

-- September 8, 2026 --

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting Globe Newswire 7:00 AM

-- September 1, 2026 --

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- August 6, 2026 --

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:15 PM

-- August 3, 2026 --

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- July 7, 2026 --

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- July 1, 2026 --

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors Globe Newswire 7:00 AM

-- June 1, 2026 --

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- May 27, 2026 --

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference Globe Newswire 7:00 AM

-- May 6, 2026 --

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:15 AM

-- April 29, 2026 --

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes